Top Markets
#1 Black Phoenix Black Phoenix +195.60%
#2 Islamic Coin Islamic Coin +158.06%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +28.16%
#5 Acurast Acurast +25.86%
#6 Cryptopia Cryptopia +21.79%
#7 Quantum Resistant Ledger Quantum Resistant Ledger +17.72%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
#9 Playnance Playnance +13.33%
#10 wojak wojak +12.65%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Timber Pharmaceuticals, Inc. Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals, Inc.

TMBR
Rangering i aksjer #42059
Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the research, development, and market introduction of treatments for rare dermatological conditions. The company's key product candidates include: TMB-001, a patented topical isotretinoin formulation, which has successfully completed Phase 2b clinical trials. It is designed to address moderate to severe forms of Congenital Ichthyosis (CI), a group of uncommon genetic disorders affecting skin keratinization. TMB-002, a proprietary topical rapamycin, currently undergoing Phase 2b clinical trials. This therapy targets facial angiofibroma associated with Tuberous Sclerosis Complex, a complex genetic disorder characterized by the growth of benign tumors in multiple organs. TMB-003, a unique Sitaxsentan formulation functioning as a selective endothelin-A receptor antagonist, which is in preclinical development for various sclerotic skin diseases. Additionally, through a licensing agreement with AFT Pharmaceuticals Limited, Timber Pharmaceuticals is advancing two topical minocycline therapies: BPX-01, now in Phase 3 development for treating inflammatory lesions of acne vulgaris. BPX-04, which is prepared for Phase 3 trials, targeting papulopustular rosacea. Founded in 2019, Timber Pharmaceuticals is headquartered in Basking Ridge, New Jersey.
Aksjekurs
$0.0101
Sist synkronisert: 2023-12-26
Markedsverdi
$5.32K
Endring (1 dag)
741.67%
Endring (1 år)
0.00%
Land
US
Handel Timber Pharmaceuticals, Inc. (TMBR)

Kategori

Healthcare
P/E-forhold for Timber Pharmaceuticals, Inc. (TMBR)
P/E-forhold per 2026 TTM: 0
Ifølge Timber Pharmaceuticals, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Timber Pharmaceuticals, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.